Perbandingan Uji Diagnostik Mesothelin Serum dengan CA-125 pada Kanker Ovarium Tipe Epitel
Abstract
Keywords
DOI: 10.33371/ijoc.v9i2.379
Article Metrics


References
Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga
M, et al. Preoperative plasma osteopontin level as a biomarker
complementary to carbohydrate antigen 125 in predicting
ovarian cancer. The Journal of Obstetrics and Gynaecology
Research 2006;32(3):309-14.
Skates SJ, Jacobs IJ, Knapp RC. Tumor markers in screening
for ovarian cancer. Methods In Molecular Medicine 2001;39:61-
Helzlsouer KJ. Prospective Study of Serum CA-125 Levels as
Markers of Ovarian Cancer. JAMA 1993;269(9):1123.
Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et
al. Elevation of multiple serum markers in patients with
stage I ovarian cancer. Journal of the National Cancer Institute
;85(21):1748-51.
Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances
and controversy. Clinical Chemistry 1998;44(7):1379-80.
Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi
N, et al. Molecular cloning and expression of megakaryocyte
potentiating factor cDNA. The Journal of Biological Chemistry
;270(37):21984-90.
Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation
antigen present on mesothelium, mesotheliomas, and ovarian
cancers. Proc Natl Acad Sci USA 1996;93(1):136-40.
Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz
ER, Cerilli LA. Mesothelin and GPR30 staining among a
spectrum of pancreatic epithelial neoplasms. International
Journal of Surgical Pathology 2011;19(5):588-96.
Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-
Ong GL, Berg K, et al. Highly expressed genes in pancreatic
ductal adenocarcinomas: a comprehensive characterization and
comparison of the transcription profiles obtained from three
major technologies. Cancer Research 2003;63(24):8614-22.
Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald
D, et al. Mesothelin expression in human lung cancer. Clinical
cancer research: an official journal of the American Association
for Cancer Research 2007;13(5):1571-5.
Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A,
Yamada S, et al. Clinical significance of serum vascular
endothelial growth factor in malignant pleural mesothelioma.
Journal of thoracic oncology: official publication of the
International Association for the Study of Lung Cancer
;5(4):479-83.
Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor
F, Meyer A, et al. Inhibition of mesothelin as a novel strategy
for targeting cancer cells. Plos One 2012;7(4):e33214.
Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao
TL, et al. Mesothelin enhances invasion of ovarian cancer by
inducing MMP-7 through MAPK/ERK and JNK pathways. The
Biochemical Journal 2012;442(2):293-302.
Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD,
Rosenshein NB, et al. Large-scale serial analysis of gene
expression reveals genes differentially expressed in ovarian
cancer. Cancer Research 2000;60(22):6281-7.
Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL,
et al. Serum mesothelin in epithelial ovarian carcinoma: a
new screening marker and prognostic factor. Anticancer
Research 2006;26(6C):4721-8.
Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD,
Pingpank J, et al. Detection and quantitation of serum mesothelin,
a tumor marker for patients with mesothelioma and ovarian
cancer. Clinical cancer research: an official journal of the
American Association for Cancer Research 2006;12(2):447-53.
Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A.
Potential markers for detection and monitoring of ovarian
cancer. J Oncol. 2011;2011:475983.
Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA,
Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein
is a biomarker for ovarian carcinoma. Cancer Research
;63(13):3695-700.
McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N,
Hellstrom KE, et al. Combining CA 125 and SMR serum
markers for diagnosis and early detection of ovarian carcinoma.
Gynecologic Oncology 2004;95(1):9-15.
Clarke-Pearson DL. Clinical practice. Screening for ovarian
cancer. NEJM 2009;361(2):170-7.
Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB.
Ovarian cancer screening and early detection in the general
population. Reviews in Obstetrics & Gynecology 2011;4(1):15-21.
Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I,
Hellstrom KE, et al. MESOMARK: a potential test for malignant
pleural mesothelioma. Clinical Chemistry 2007;53(4):666-72.
Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P.
Preoperative CA 125: an independent prognostic factor in
patients with stage I epithelial ovarian cancer. Obstetrics
and Gynecology 1995;86(2):259-64.
Malati T. Tumour markers: An overview. IJCB 2007;22(2):17-31.
Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs
C, et al. Large prospective study of ovarian cancer screening
in high-risk women: CA125 cut-point defined by menopausal
status. Cancer Prevention Research 2011;4(9):1401-8.
Collaborative Group on Epidemiological Studies of Ovarian
C, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer
and oral contraceptives: collaborative reanalysis of data from
epidemiological studies including 23,257 women with ovarian
cancer and 87,303 controls. Lancet 2008;371(9609):303-14.
Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model
in evolution. J Oncol. 2010;2010:932371.
Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4
as a biomarker for ovarian and endometrial cancer management.
Expert Review of Molecular Diagnostics 2009;9(6):555-66.
Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and
mesothelin: novel biomarkers of ovarian carcinoma in patients
with pelvic masses. APJCP 2010;11(1):111-6.
Refbacks
- There are currently no refbacks.